查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1308641

2030 年病毒清除市场预测 - 按方法、应用、最终用户和地区进行的全球分析

Viral Clearance Market Forecasts to 2030 - Global Analysis By Method, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球病毒清除市场规模将达到 7.6464 亿美元，预计到 2030 年将达到 19.3815 亿美元，预测期内復合年增长率为 14.21%。

重组蛋白、糖蛋白、组织和血液衍生产品、医疗器械和单克隆抗体的开发都依赖于病毒清除过程。动物和人类细胞都可以被病毒感染，但病毒具有自我复制的能力。它还具有在细菌宿主细胞内繁殖和传播的能力，造成损害和感染。病毒清除方法的一个关键组成部分是评估无风险生产产品并确保其人类使用安全的能力。原材料、下游工艺、细胞培养过程都会受到病毒感染的影响。这将有助于病毒安全实践的发展和病毒清除流程的实施。

据 BioSpace 称，2018 年有 386 种药物註册用于临床开发，而 2008 年仅为 178 种。开发过程中的药物数量不断增加，对病毒清除服务的需求也随之增加。

市场动态：

主持人：

慢性病增加

推动病毒灭活市场增长的因素包括慢性病毒感染和疾病患病率的上升以及对有效治疗的需求增加。由于生命科学行业投资的增加、新药引进的增加以及研发创新的增加，预计该市场还将增长。

抑製剂

最先进的技术带来高成本

阻碍市场发展的是产品和技术开发成本过高。此外，缓慢的药物开发过程以及与病毒清除相关的几个问题（例如蛋白质交联、蛋白质变性和蛋白质降解）限制了市场的扩张。

机会：

加强病毒安全监管

病毒安全评估是确保产品安全的重要一步。监管机构认真对待病毒安全性，并需要復杂的数据来支持它，特别是 IND 和 BLA 批准。了解监管要求、流程和流程关键领域对于有效的战略规划至关重要。药物开发中的此类病毒安全法规正在增加对使试验更加成功的服务的需求。

威胁

缺乏合格的专业人员

作为病毒清除服务提供商，与製药公司、生物技术公司、医疗器械公司以及研究和学术机构竞争有才华和经验丰富的科学家，招聘和留住高技能专业人员是我面临的挑战。为了在竞争中保持领先地位，公司必须提供更高的薪酬和其他激励措施，这反过来又会影响尤其是规模较小的分析测试提供商的财务和财务绩效。熟练专业人员的短缺阻碍了新技术和工艺的采用，并可能限制未来几年的市场增长。

COVID-19 的影响：

市场受到 COVID-19 大流行的负面影响。劳动力和人员短缺、感染传播的风险以及生物製药和生物技术领域的生产停滞是市场面临的挑战。然而，2021年，市场增长急剧加速。这种增长归因于临床试验的增加。为了开发针对SARS-CoV-2病毒的疫苗和药物，许多製药和生物製药公司增加了研发和製造流程。此外，自 COVID-19 爆发以来，与製药公司和学术机构就 COVID-19 疫苗开发建立了许多新的全球伙伴关係和合作。

在预测期内，重组蛋白行业预计将是最大的：

预计重组蛋白领域将在预测期内占据最大的市场份额。影响该领域增长的主要因素之一是对治疗牛皮癣、多发性硬化症、风湿病和炎症性肠病等炎症性疾病的生物製药的需求不断增长。随着重组蛋白的引入，生物製药的生产和开发已经彻底改变。随着许多由重组蛋白製成的生物製剂和疫苗正在研发中并预计将获得 FDA 的批准，重组药物的数量预计将增长。因此，考虑到上述所有因素，预计市场将会增长。

合同研究组织部门预计在预测期内復合年增长率最高：

随着主要市场进入者增加对各种研究机构的投资以改进产品，预计未来几年合同研究机构市场将出现强劲增长。合同研究机构大力投资药物发现基础设施的能力以及初创企业、学术机构、製药公司和小型生物技术公司等组织越来越多地将药物发现服务外包给 CRO 是推动全球需求的一个关键因素。美国病毒清除市场的非凡增长。

占比最大的地区：

预计北美将在整个预测期内主导病毒清除市场。重要参与者的存在及其对尖端医疗技术的进步是获得最大份额的主要因素。市场扩张的主要驱动力是重组蛋白和疫苗产量的增加以及保护它们免受病毒和风险影响的需要。此外，人们对使用生物製药的好处的认识不断增强，增加了对病毒清除相关服务的需求。此外，由于美国各地药品资金的增加，市场正在扩大。

复合年增长率最高的地区：

由于政府对医学研究的投资增加和医疗保健成本飙升，以及中国、日本和印度等国家细胞培养物污染和 CRO 存在的风险增加，预计亚太地区在预测期内将出现显着增长. 增加。据世界卫生组织统计，超过1500万年龄在35岁至69岁之间的人死于慢性病，其中发达国家和发展中国家均占过早死亡的85%。此外，还有许多临床研究服务，尤其是在中国，预计将刺激未来市场的扩张。

重大发展

2022 年 9 月，Merck将开设病毒清除 (VC) 实验室，作为其耗资 2,900 万欧元新建的中国生物製品检测中心 1 号楼的一部分。

2022 年 4 月，研究员 (PRO) Abzena 宣布在其位于加利福尼亚州圣地亚哥的生物製剂工艺开发和製造中心附近开设一个生物製剂测试实验室。该设施将为合作伙伴提供基于细胞和 PCR 安全检测、病毒清除研究的机会，以支持 IND、IMPD、BLA 和 MAA 提交。

2022年4月，WuXi Biologics荣获亚太生物工艺卓越奖（ABEA）第二届病毒清除和安全性生物工艺卓越奖。

报告内容

  • 区域和国家层面的市场份额评估
  • 对新进入者的战略建议
  • 涵盖 2021、2022、2023、2026 和 2030 年的市场数据
  • 市场趋势
  • 根据市场预测提出关键业务领域的战略建议
  • 竞争格局映射关键共同趋势
  • 公司概况，包括详细战略、财务状况和近期发展
  • 映射最新技术进步的供应链趋势

免费定制服务：

订阅此报告的客户将获得以下免费定制选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要公司的SWOT分析（最多3家公司）
  • 地理细分
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（注：通过可行性检查）
  • 竞争标桿
    • 根据产品组合、地域分布和战略联盟对主要参与者进行基准测试

目录

第一章内容提要

第二章前言

  • 执行摘要
  • 利益相关者
  • 调查范围
  • 调查方法
    • 数据挖掘
    • 数据分析
    • 数据验证
    • 研究方法
  • 研究来源
    • 主要研究来源
    • 二次研究来源
    • 先决条件

第三章市场趋势分析

  • 促进者
  • 抑製剂
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5 全球病毒清除市场（按方法）

  • 病毒清除
    • 色谱法
    • 纳滤
    • 沉淀法
  • 病毒灭活
    • 低pH值
    • 溶剂清洗法
    • 加热灭菌
    • 其他病毒灭活方法
  • 病毒检测方法

6. 全球病毒清除市场（按应用）

  • 重组蛋白
  • 血液和血液製品
  • 细胞和基因治疗产品
  • 疫苗接种
  • 其他用途

7. 全球病毒清除市场（按最终用户）

  • 製药和生物技术公司
  • 学术研究所
  • 合同研究所
  • 其他最终用户

8. 全球病毒清除市场（按地区）

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 意大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 新西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东/非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 卡塔尔
    • 南非
    • 其他中东和非洲

第九章 主要进展

  • 协议、伙伴关係、协会和合资企业
  • 收购与合併
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十章公司简介

  • Avance Biosciences Inc.
  • BioReliance Corporation
  • Bioscience Laboratories
  • BSL Bioservice Scientific Laboratories GmbH
  • Charles River Laboratories, Inc.
  • Clean Cells Inc.
  • Cytovance Biologics Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare Life Sciences
  • Kedrion Biopharma Inc.
  • Labor Dr. Merk & Kollegen GmbH
  • Lonza Group AG
  • Merck KGaA
  • Nelson Laboratories LLC
  • Novartis AG
  • Sartorius AG
  • Sigma-Aldrich Corporation
  • Syngene International Limited
  • Texcell, Inc.
  • Vironova AB
  • ViruSure GmbH
  • WuXi AppTec
Product Code: SMRC23341

According to Stratistics MRC, the Global Viral Clearance Market is accounted for $764.64 million in 2023 and is expected to reach $1938.15 million by 2030 growing at a CAGR of 14.21% during the forecast period. The development of recombinant proteins, glycoproteins, tissue- and blood-derived products, medical devices, and monoclonal antibodies all depend on the viral clearance process. Animal or human cells can become infected by viruses, which have the capacity to multiply on their own. Additionally, they have the power to multiply and spread within the host cell of bacteria, causing damage and infection. An important component of the viral clearance method is the evaluation of the capacity to produce a product without risk and guarantee the product's safety for human use. Raw materials, downstream processing, and cell culture processes are all impacted by viral infections. This would contribute to the development of viral safety practices and the implementation of the virus clearance process.

According to BioSpace, in 2018, 386 drugs were registered for clinical development, observing a significant growth from 2008, when the number of drugs was only 178. The increase in the number of drugs in the development process has increased viral clearing services' demand.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

Some of the factors propelling the growth of the viral inactivation market include the rising prevalence of chronic viral infections and diseases and the rising demand for effective treatment methods. Additionally, the market is expected to grow as a result of rising investment in the life sciences industry, the introduction of more new drugs, and increased R&D innovation.

Restraint:

High costs incurred by cutting-edge technologies

The market expansion is being hampered by high development costs for goods and technology. Additionally, the lengthy drug development process and some issues related to virus clearance, such as protein crosslinking, protein denaturation, and protein degradation, are restricting the market's expansion.

Opportunity:

Increasing viral safety regulations

The evaluation of viral safety is an important step in ensuring the safety of products. Regulatory agencies place a lot of emphasis on viral safety and demand high-caliber data to support it, particularly for IND and BLA approvals. For effective strategic planning, it is crucial to be knowledgeable about the regulatory requirements, the process, and the key areas of the process. These viral safety regulations during the development of pharmaceutical products have increased the demand for services to conduct studies more successfully.

Threat:

Scarcity of qualified specialists

Virus removal service providers face challenges in attracting and retaining highly skilled professionals as they compete for qualified and experienced scientists with pharmaceutical companies, biotechnology companies, medical device companies, and research and academic institutions. Companies have to offer higher compensation and other incentives to compete, which affects the finances and performance of players, especially smaller analytics test providers. This scarcity of skilled professionals may hinder the adoption of new technologies and processes, limiting the growth of the market in the coming years.

COVID-19 Impact:

The market was negatively impacted by the COVID-19 pandemic. The market was challenged by a lack of workers and staff, a risk of infection spread, and a slowdown in manufacturing in the biopharmaceutical and biotech sectors. However, the market witnessed a sharp acceleration in growth in 2021. This growth was attributed to an increase in clinical trials. To develop vaccines and medications against the SARS-CoV-2 virus, many pharmaceutical and biopharmaceutical companies increased their R&D and manufacturing processes. Additionally, following the COVID-19 outbreak, there have been numerous new global partnerships and collaborations with pharmaceutical companies and academic institutions for the development of COVID-19 vaccines.

The recombinant proteins segment is expected to be the largest during the forecast period:

During the forecast period, the recombinant proteins segment is anticipated to hold the largest market share. One of the main factors influencing the segment's growth is the rising demand for biopharmaceuticals for managing inflammatory diseases like psoriasis, multiple sclerosis, rheumatic diseases, and inflammatory bowel diseases. The production and development of biotherapeutics have been completely transformed by the introduction of recombinant proteins. As numerous biologics and vaccines made of recombinant proteins are currently in the pipeline and are anticipated to receive FDA approval, it is anticipated that the number of recombinant drugs will increase. The market is therefore anticipated to grow in light of all the aforementioned factors.

The contract research organizations segment is expected to have the highest CAGR during the forecast period:

Due to growing investments by major market players in various research organizations to improve their products, the contract research organizations segment is anticipated to experience strong market growth in the upcoming years. The ability of contract research organizations to make significant investments in drug discovery infrastructure and an increase in the outsourcing of drug discovery services to CROs by organizations like start-ups, academic institutions, pharmaceutical companies, and small biotechnology companies are the main factors behind their extraordinary growth in the global viral clearance market.

Region with largest share:

Throughout the forecast period, North America is anticipated to dominate the viral clearance market. The presence of important players and their use of cutting-edge medical technologies to advance are primarily responsible for the largest share. The primary driver of market expansion is the rise in the production of recombinant proteins and vaccines, as well as the requirement to keep them virus- and risk-free. Additionally, the population is becoming more aware of the benefits of using biopharmaceuticals, which is driving up demand for services related to viral clearance. Furthermore, the market is expanding as a result of increased funding for pharmaceuticals across the United States.

Region with highest CAGR:

Due to rising government investments in medical research and rising healthcare costs, Asia Pacific is expected to grow significantly during the forecast period, which will increase the risk of cell culture contamination and the presence of CROs in nations like China, Japan, and India. According to statistics from the WHO, more than 15 million people between the ages of 35 and 69 die from chronic diseases, and both developed and developing nations account for 85% of premature deaths. Additionally, a large number of clinical research services, particularly in China, are anticipated to fuel market expansion in the upcoming years.

Key players in the market

Some of the key players profiled in the Viral Clearance Market include Avance Biosciences Inc., BioReliance Corporation, Bioscience Laboratories, BSL Bioservice Scientific Laboratories GmbH, Charles River Laboratories, Inc., Clean Cells Inc., Cytovance Biologics Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd., GE Healthcare Life Sciences, Kedrion Biopharma Inc., Labor Dr. Merk & Kollegen GmbH, Lonza Group AG, Merck KGaA, Nelson Laboratories LLC, Novartis AG, Sartorius AG, Sigma-Aldrich Corporation, Syngene International Limited, Texcell, Inc., Vironova AB, ViruSure GmbH and WuXi AppTec.

Key Developments:

In September 2022, Merck opened a viral clearance (VC) laboratory as part of the first building phase of its new EUR 29 million China Biologics Testing Center.

In April 2022, Abzena, a partner research organization (PRO), announced the opening of a biologics testing laboratory situated near the company's biologics process development and manufacturing hub in San Diego, California. The facility will give partners access to cell-based and PCR safety assays; and viral clearance studies to support their IND, IMPD, BLA, and MAA applications.

In April 2022, WuXi Biologics awarded the bioprocessing excellence in viral clearance and safety accolade for the second time at the Asia Pacific Bioprocessing Excellence Awards (ABEA) event.

Methods Covered:

  • Viral Removal
  • Viral Inactivation
  • Viral Detection Method

Application Covered:

  • Recombinant Proteins
  • Blood and Blood Products
  • Cellular and Gene Therapy Products
  • Vaccines
  • Other Applications

End Users Covered:

  • Pharmaceutical and Biotechnology Companies
  • Academic Research Institutes
  • Contract Research Organizations
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026 and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Viral Clearance Market, By Method

  • 5.1 Introduction
  • 5.2 Viral Removal
    • 5.2.1 Chromatography
    • 5.2.2 Nanofiltration
    • 5.2.3 Precipitation
  • 5.3 Viral Inactivation
    • 5.3.1 Low pH
    • 5.3.2 Solvent Detergent Method
    • 5.3.3 Heat Pasteurization
    • 5.3.4 Other Viral Inactivation Methods
  • 5.4 Viral Detection Method

6 Global Viral Clearance Market, By Application

  • 6.1 Introduction
  • 6.2 Recombinant Proteins
  • 6.3 Blood and Blood Products
  • 6.4 Cellular and Gene Therapy Products
  • 6.5 Vaccines
  • 6.6 Other Applications

7 Global Viral Clearance Market, By End User

  • 7.1 Introduction
  • 7.2 Pharmaceutical and Biotechnology Companies
  • 7.3 Academic Research Institutes
  • 7.4 Contract Research Organizations
  • 7.5 Other End Users

8 Global Viral Clearance Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Avance Biosciences Inc.
  • 10.2 BioReliance Corporation
  • 10.3 Bioscience Laboratories
  • 10.4 BSL Bioservice Scientific Laboratories GmbH
  • 10.5 Charles River Laboratories, Inc.
  • 10.6 Clean Cells Inc.
  • 10.7 Cytovance Biologics Inc.
  • 10.8 Eurofins Scientific
  • 10.9 F. Hoffmann-La Roche Ltd.
  • 10.10 GE Healthcare Life Sciences
  • 10.11 Kedrion Biopharma Inc.
  • 10.12 Labor Dr. Merk & Kollegen GmbH
  • 10.13 Lonza Group AG
  • 10.14 Merck KGaA
  • 10.15 Nelson Laboratories LLC
  • 10.16 Novartis AG
  • 10.17 Sartorius AG
  • 10.18 Sigma-Aldrich Corporation
  • 10.19 Syngene International Limited
  • 10.20 Texcell, Inc.
  • 10.21 Vironova AB
  • 10.22 ViruSure GmbH
  • 10.23 WuXi AppTec

List of Tables

  • Table 1 Global Viral Clearance Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Viral Clearance Market Outlook, By Method (2021-2030) ($MN)
  • Table 3 Global Viral Clearance Market Outlook, By Viral Removal (2021-2030) ($MN)
  • Table 4 Global Viral Clearance Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 5 Global Viral Clearance Market Outlook, By Nanofiltration (2021-2030) ($MN)
  • Table 6 Global Viral Clearance Market Outlook, By Precipitation (2021-2030) ($MN)
  • Table 7 Global Viral Clearance Market Outlook, By Viral Inactivation (2021-2030) ($MN)
  • Table 8 Global Viral Clearance Market Outlook, By Low pH (2021-2030) ($MN)
  • Table 9 Global Viral Clearance Market Outlook, By Solvent Detergent Method (2021-2030) ($MN)
  • Table 10 Global Viral Clearance Market Outlook, By Heat Pasteurization (2021-2030) ($MN)
  • Table 11 Global Viral Clearance Market Outlook, By Other Viral Inactivation Methods (2021-2030) ($MN)
  • Table 12 Global Viral Clearance Market Outlook, By Viral Detection Method (2021-2030) ($MN)
  • Table 13 Global Viral Clearance Market Outlook, By Application (2021-2030) ($MN)
  • Table 14 Global Viral Clearance Market Outlook, By Recombinant Proteins (2021-2030) ($MN)
  • Table 15 Global Viral Clearance Market Outlook, By Blood and Blood Products (2021-2030) ($MN)
  • Table 16 Global Viral Clearance Market Outlook, By Cellular and Gene Therapy Products (2021-2030) ($MN)
  • Table 17 Global Viral Clearance Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 18 Global Viral Clearance Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 19 Global Viral Clearance Market Outlook, By End User (2021-2030) ($MN)
  • Table 20 Global Viral Clearance Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 21 Global Viral Clearance Market Outlook, By Academic Research Institutes (2021-2030) ($MN)
  • Table 22 Global Viral Clearance Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 23 Global Viral Clearance Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 24 North America Viral Clearance Market Outlook, By Country (2021-2030) ($MN)
  • Table 25 North America Viral Clearance Market Outlook, By Method (2021-2030) ($MN)
  • Table 26 North America Viral Clearance Market Outlook, By Viral Removal (2021-2030) ($MN)
  • Table 27 North America Viral Clearance Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 28 North America Viral Clearance Market Outlook, By Nanofiltration (2021-2030) ($MN)
  • Table 29 North America Viral Clearance Market Outlook, By Precipitation (2021-2030) ($MN)
  • Table 30 North America Viral Clearance Market Outlook, By Viral Inactivation (2021-2030) ($MN)
  • Table 31 North America Viral Clearance Market Outlook, By Low pH (2021-2030) ($MN)
  • Table 32 North America Viral Clearance Market Outlook, By Solvent Detergent Method (2021-2030) ($MN)
  • Table 33 North America Viral Clearance Market Outlook, By Heat Pasteurization (2021-2030) ($MN)
  • Table 34 North America Viral Clearance Market Outlook, By Other Viral Inactivation Methods (2021-2030) ($MN)
  • Table 35 North America Viral Clearance Market Outlook, By Viral Detection Method (2021-2030) ($MN)
  • Table 36 North America Viral Clearance Market Outlook, By Application (2021-2030) ($MN)
  • Table 37 North America Viral Clearance Market Outlook, By Recombinant Proteins (2021-2030) ($MN)
  • Table 38 North America Viral Clearance Market Outlook, By Blood and Blood Products (2021-2030) ($MN)
  • Table 39 North America Viral Clearance Market Outlook, By Cellular and Gene Therapy Products (2021-2030) ($MN)
  • Table 40 North America Viral Clearance Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 41 North America Viral Clearance Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 42 North America Viral Clearance Market Outlook, By End User (2021-2030) ($MN)
  • Table 43 North America Viral Clearance Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 44 North America Viral Clearance Market Outlook, By Academic Research Institutes (2021-2030) ($MN)
  • Table 45 North America Viral Clearance Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 46 North America Viral Clearance Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 47 Europe Viral Clearance Market Outlook, By Country (2021-2030) ($MN)
  • Table 48 Europe Viral Clearance Market Outlook, By Method (2021-2030) ($MN)
  • Table 49 Europe Viral Clearance Market Outlook, By Viral Removal (2021-2030) ($MN)
  • Table 50 Europe Viral Clearance Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 51 Europe Viral Clearance Market Outlook, By Nanofiltration (2021-2030) ($MN)
  • Table 52 Europe Viral Clearance Market Outlook, By Precipitation (2021-2030) ($MN)
  • Table 53 Europe Viral Clearance Market Outlook, By Viral Inactivation (2021-2030) ($MN)
  • Table 54 Europe Viral Clearance Market Outlook, By Low pH (2021-2030) ($MN)
  • Table 55 Europe Viral Clearance Market Outlook, By Solvent Detergent Method (2021-2030) ($MN)
  • Table 56 Europe Viral Clearance Market Outlook, By Heat Pasteurization (2021-2030) ($MN)
  • Table 57 Europe Viral Clearance Market Outlook, By Other Viral Inactivation Methods (2021-2030) ($MN)
  • Table 58 Europe Viral Clearance Market Outlook, By Viral Detection Method (2021-2030) ($MN)
  • Table 59 Europe Viral Clearance Market Outlook, By Application (2021-2030) ($MN)
  • Table 60 Europe Viral Clearance Market Outlook, By Recombinant Proteins (2021-2030) ($MN)
  • Table 61 Europe Viral Clearance Market Outlook, By Blood and Blood Products (2021-2030) ($MN)
  • Table 62 Europe Viral Clearance Market Outlook, By Cellular and Gene Therapy Products (2021-2030) ($MN)
  • Table 63 Europe Viral Clearance Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 64 Europe Viral Clearance Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 65 Europe Viral Clearance Market Outlook, By End User (2021-2030) ($MN)
  • Table 66 Europe Viral Clearance Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 67 Europe Viral Clearance Market Outlook, By Academic Research Institutes (2021-2030) ($MN)
  • Table 68 Europe Viral Clearance Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 69 Europe Viral Clearance Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 70 Asia Pacific Viral Clearance Market Outlook, By Country (2021-2030) ($MN)
  • Table 71 Asia Pacific Viral Clearance Market Outlook, By Method (2021-2030) ($MN)
  • Table 72 Asia Pacific Viral Clearance Market Outlook, By Viral Removal (2021-2030) ($MN)
  • Table 73 Asia Pacific Viral Clearance Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 74 Asia Pacific Viral Clearance Market Outlook, By Nanofiltration (2021-2030) ($MN)
  • Table 75 Asia Pacific Viral Clearance Market Outlook, By Precipitation (2021-2030) ($MN)
  • Table 76 Asia Pacific Viral Clearance Market Outlook, By Viral Inactivation (2021-2030) ($MN)
  • Table 77 Asia Pacific Viral Clearance Market Outlook, By Low pH (2021-2030) ($MN)
  • Table 78 Asia Pacific Viral Clearance Market Outlook, By Solvent Detergent Method (2021-2030) ($MN)
  • Table 79 Asia Pacific Viral Clearance Market Outlook, By Heat Pasteurization (2021-2030) ($MN)
  • Table 80 Asia Pacific Viral Clearance Market Outlook, By Other Viral Inactivation Methods (2021-2030) ($MN)
  • Table 81 Asia Pacific Viral Clearance Market Outlook, By Viral Detection Method (2021-2030) ($MN)
  • Table 82 Asia Pacific Viral Clearance Market Outlook, By Application (2021-2030) ($MN)
  • Table 83 Asia Pacific Viral Clearance Market Outlook, By Recombinant Proteins (2021-2030) ($MN)
  • Table 84 Asia Pacific Viral Clearance Market Outlook, By Blood and Blood Products (2021-2030) ($MN)
  • Table 85 Asia Pacific Viral Clearance Market Outlook, By Cellular and Gene Therapy Products (2021-2030) ($MN)
  • Table 86 Asia Pacific Viral Clearance Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 87 Asia Pacific Viral Clearance Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 88 Asia Pacific Viral Clearance Market Outlook, By End User (2021-2030) ($MN)
  • Table 89 Asia Pacific Viral Clearance Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 90 Asia Pacific Viral Clearance Market Outlook, By Academic Research Institutes (2021-2030) ($MN)
  • Table 91 Asia Pacific Viral Clearance Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 92 Asia Pacific Viral Clearance Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 93 South America Viral Clearance Market Outlook, By Country (2021-2030) ($MN)
  • Table 94 South America Viral Clearance Market Outlook, By Method (2021-2030) ($MN)
  • Table 95 South America Viral Clearance Market Outlook, By Viral Removal (2021-2030) ($MN)
  • Table 96 South America Viral Clearance Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 97 South America Viral Clearance Market Outlook, By Nanofiltration (2021-2030) ($MN)
  • Table 98 South America Viral Clearance Market Outlook, By Precipitation (2021-2030) ($MN)
  • Table 99 South America Viral Clearance Market Outlook, By Viral Inactivation (2021-2030) ($MN)
  • Table 100 South America Viral Clearance Market Outlook, By Low pH (2021-2030) ($MN)
  • Table 101 South America Viral Clearance Market Outlook, By Solvent Detergent Method (2021-2030) ($MN)
  • Table 102 South America Viral Clearance Market Outlook, By Heat Pasteurization (2021-2030) ($MN)
  • Table 103 South America Viral Clearance Market Outlook, By Other Viral Inactivation Methods (2021-2030) ($MN)
  • Table 104 South America Viral Clearance Market Outlook, By Viral Detection Method (2021-2030) ($MN)
  • Table 105 South America Viral Clearance Market Outlook, By Application (2021-2030) ($MN)
  • Table 106 South America Viral Clearance Market Outlook, By Recombinant Proteins (2021-2030) ($MN)
  • Table 107 South America Viral Clearance Market Outlook, By Blood and Blood Products (2021-2030) ($MN)
  • Table 108 South America Viral Clearance Market Outlook, By Cellular and Gene Therapy Products (2021-2030) ($MN)
  • Table 109 South America Viral Clearance Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 110 South America Viral Clearance Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 111 South America Viral Clearance Market Outlook, By End User (2021-2030) ($MN)
  • Table 112 South America Viral Clearance Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 113 South America Viral Clearance Market Outlook, By Academic Research Institutes (2021-2030) ($MN)
  • Table 114 South America Viral Clearance Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 115 South America Viral Clearance Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 116 Middle East & Africa Viral Clearance Market Outlook, By Country (2021-2030) ($MN)
  • Table 117 Middle East & Africa Viral Clearance Market Outlook, By Method (2021-2030) ($MN)
  • Table 118 Middle East & Africa Viral Clearance Market Outlook, By Viral Removal (2021-2030) ($MN)
  • Table 119 Middle East & Africa Viral Clearance Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 120 Middle East & Africa Viral Clearance Market Outlook, By Nanofiltration (2021-2030) ($MN)
  • Table 121 Middle East & Africa Viral Clearance Market Outlook, By Precipitation (2021-2030) ($MN)
  • Table 122 Middle East & Africa Viral Clearance Market Outlook, By Viral Inactivation (2021-2030) ($MN)
  • Table 123 Middle East & Africa Viral Clearance Market Outlook, By Low pH (2021-2030) ($MN)
  • Table 124 Middle East & Africa Viral Clearance Market Outlook, By Solvent Detergent Method (2021-2030) ($MN)
  • Table 125 Middle East & Africa Viral Clearance Market Outlook, By Heat Pasteurization (2021-2030) ($MN)
  • Table 126 Middle East & Africa Viral Clearance Market Outlook, By Other Viral Inactivation Methods (2021-2030) ($MN)
  • Table 127 Middle East & Africa Viral Clearance Market Outlook, By Viral Detection Method (2021-2030) ($MN)
  • Table 128 Middle East & Africa Viral Clearance Market Outlook, By Application (2021-2030) ($MN)
  • Table 129 Middle East & Africa Viral Clearance Market Outlook, By Recombinant Proteins (2021-2030) ($MN)
  • Table 130 Middle East & Africa Viral Clearance Market Outlook, By Blood and Blood Products (2021-2030) ($MN)
  • Table 131 Middle East & Africa Viral Clearance Market Outlook, By Cellular and Gene Therapy Products (2021-2030) ($MN)
  • Table 132 Middle East & Africa Viral Clearance Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 133 Middle East & Africa Viral Clearance Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 134 Middle East & Africa Viral Clearance Market Outlook, By End User (2021-2030) ($MN)
  • Table 135 Middle East & Africa Viral Clearance Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 136 Middle East & Africa Viral Clearance Market Outlook, By Academic Research Institutes (2021-2030) ($MN)
  • Table 137 Middle East & Africa Viral Clearance Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 138 Middle East & Africa Viral Clearance Market Outlook, By Other End Users (2021-2030) ($MN)